

Course Detail

MMWR Weekly –January 11, 2013

Course Number: SS1747-01112013

CE Origination Date: January 11, 2013

CE Expiration Date: February 25, 2013

Content Experts/Prepares

Thrombotic Thrombocytopenic Purpura (TTP)–Like Illness Associated with Intravenous Opana ER Abuse — Tennessee, 2012

John Dunn, DVM, Tennessee Department of Health

Timothy F. Jones, MD, Tennessee Department of Health

David Kirschke, MD, Tennessee Department of Health

Ellyn Marder, MPH, Tennessee Department of Health

Donna Robbins, DrPH, Tennessee Department of Health

Judy Racoosin, MD, Division of Anesthesia, Analgesia, and Addiction Products, Center for Drug Evaluation and Research, Food and Drug Administration

Leonard Paulozzi, MD, Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC

Art Chang, MD, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, CDC

Published Reports of Delayed Hemolytic Anemia After Treatment with Artesunate for Severe Malaria — Worldwide, 2010–2012

Paul M. Arguin, MD, Division of Parasitic Diseases and Malaria, CDC

Melissa Briggs, MD, Division of Parasitic Diseases and Malaria, CDC

Vital Signs: Binge Drinking Among Women and High School Girls — United States, 2011

Robert D. Brewer, MD, Division of Population Health, CDC

Paul I. Eke, PhD, Division of Population Health, CDC

Dafna Kanny, PhD, Division of Population Health, CDC

Yong Liu, MS, Division of Population Health, CDC

Shanna N. Cox, MSPH, Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC

Nancy E. Cheal, PhD, Division of Birth Defects and Developmental Disabilities, National Center for Birth Defects and Developmental Disabilities, CDC

Yvonne Green, MSN, Office of Women’s Health, CDC

Disclosure

CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.

No commercial support.

Mechanism(s) to Resolve Real and Perceived Conflicts of Interest: N/A